On October 18, 2023, President Xi Jinping delivered a keynote speech at the opening ceremony of the third 'Belt and Road' International Cooperation Summit Forum and emphasized that after the outbreak of the new crown epidemic, 'One Belt and One Road' has become a road to life and health.
China has provided 2.3 billion doses of vaccines to various countries and cooperated with more than 20 countries to produce vaccines, making unique contributions to the Belt and Road partners' fight against the epidemic.
It can be seen from President Xi's speech that in the process of China's vaccine assisting the global fight against the epidemic, sharing and co-construction are the key words, and this is also the principle upheld by all parties involved in the 'Belt and Road' initiative. As a Chinese vaccine company, China Sinovac's vaccine cooperation with partners along the 'Belt and Road' began with the mission of 'providing vaccines to eliminate diseases in humans' and has also been committed to making vaccines, public health products, more accessible and affordable.
In order to showcase the results of vaccine cooperation in the 'Belt and Road' countries over the past ten years, Sinovac held a media exchange meeting on October 20. At the meeting, Yang Guang, Chief Commercial Officer of Sinovac, introduced that Sinovac has developed vaccines for COVID-19, hepatitis A, Five vaccines, including influenza, chickenpox, and pneumonia , are supplied to 62 'Belt and Road' countries, covering 41% of the 'Belt and Road' countries , and the total supply has exceeded 1.2 billion doses.
Yin Weidong, Chairman, President and CEO of Sinovac, told reporters when attending the opening ceremony of the 'Belt and Road' International Cooperation Summit Forum that the 'Belt and Road' provides a broad platform for more vaccine sharing and cooperation. On this platform, Sinovac The emerging hepatitis A, influenza, chickenpox and other vaccines can serve people in more countries. In addition to supplying vaccines, Sinovac can make external investments through the 'Belt and Road' platform, establish joint ventures, carry out R&D and production cooperation, and incubate more high-quality vaccines and even drugs under the 'Belt and Road' mechanism.
What is a high-quality vaccine World Health Organization ( WHO ) pre-certification is one of the measurement standards and is also regarded as a 'ticket' for vaccines to enter the international market. So far, eight vaccines from five vaccine manufacturers in China have passed WHO pre-certification, and Sinovac owns three of these eight 'tickets . ' Only by ensuring the high quality of vaccines can Sinovac continue to make vaccines available. So far, Sinovac's vaccines have obtained 95 marketing authorizations and emergency use authorizations in Belt and Road countries.
In addition to sharing vaccines, Sinovac also actively responds to the co-construction principle of the 'Belt and Road' and exports its vaccine production capacity through technology licensing, so that developing countries that do not have the ability to develop and produce localized vaccines can get rid of their 'vaccine dependence'. Truly making vaccines more accessible and affordable. So far, Sinovac has signed vaccine production technology licensing agreements with 12 'Belt and Road' countries.
In Turkey, Sinovac established a joint venture company KeyVac with local partners to jointly build a vaccine sub-packaging workshop to further enhance Turkey's localized production and supply capabilities for multiple vaccines; in Egypt, in addition to carrying out localized production cooperation with local partners, Sinovac It also assisted in the construction of an automated vaccine storage center, which is currently the largest vaccine storage center in Africa, greatly improving Egypt's vaccine cold chain storage and transportation capabilities.
In fact, before COVID-19, China's vaccines had been shared and co-constructed with many countries. The ability of Chinese vaccine companies such as Sinovac to develop a COVID-19 vaccine in a short period of time and ensure the high-quality supply of billions of doses of vaccine is not a one-day effort, but the result of more than two decades of unremitting cultivation and accumulation. Only in this way can Chinese vaccines benefit the world as soon as possible when an emergency public health crisis occurs.
China's new crown vaccine helps pave the 'road to life and health'
The development of a COVID-19 vaccine is time-tight and full of difficulties. With the completion of Phase I and II clinical trials in China, China's new coronavirus vaccine research and development encountered a new problem at that time - where did the volunteers for Phase III clinical research come from At that time, there was basically no natural epidemic of COVID-19 in China, and phase III clinical trials required recruiting a large number of volunteers under epidemic conditions.
In the critical stage of Phase III clinical research, Sinovac has efficiently promoted research cooperation overseas with partners from Indonesia, Turkey, Chile, South Africa and other 'Belt and Road' countries, and has achieved numerous research results that have confirmed the safety and effectiveness of the vaccine. The Sinovac COVID-19 vaccine has been approved for marketing with conditions in China, has been approved for emergency use in more than 60 countries and regions around the world, and has been included in the emergency use list by the WHO, which provides important evidence. So far, more than 700 global studies have been published related to Sinovac's COVID-19 vaccine, most of which come from 'Belt and Road' countries.
Indonesia is the first country to approve the Sinovac COVID-19 vaccine for marketing and use. On January 13, 2021, Indonesian President Joko showed his vaccination process with China's Sinovac vaccine on live television, becoming the first person in Indonesia to receive the COVID-19 vaccine. Since then, politicians from many countries, including Turkish President Erdogan, Chilean President Pinera, Dominican President Abinadel, Zimbabwean President Mnangagwa, and former Uruguay President Lacalle, have taken the lead in receiving the Sinovac COVID-19 vaccine in their countries.
After listening to President Xi's keynote speech at the opening ceremony of the 'Belt and Road' International Cooperation Summit Forum on the morning of October 18, Yin Weidong told the media that China's vaccines have made great contributions in paving the way to life and health . The unique contribution of the Belt and Road Initiative is due to President Xi Jinping's strategic planning and the sharing, co-construction and mutual assistance of many 'Belt and Road' countries. The contribution made by China's COVID-19 vaccine is an important achievement of the joint construction of the 'Belt and Road' and fulfills China's commitment to 'making vaccines a global public good.'
In the process of going global, China's new crown vaccine has also gained recognition from people in many countries along the 'Belt and Road'. At the media exchange meeting, Yang Guang shared two short stories. In the early stages of the development of the Sinovac COVID-19 vaccine, a Turkish friend sent a letter and 50 lira to Sinovac. He said that he hoped to contribute to the development of the Sinovac COVID-19 vaccine. In April 2021, Sinovac donated 50,000 doses of COVID-19 vaccine to CONMEBOL to support the smooth hosting of the 2021 America's Cup. To express his gratitude, Argentinian star Messi gave Sinovac three signed jerseys with 'Full of Love' handwritten on them.
Cooperation on the 'One Belt, One Road' initiative is actually a proposition for international development for enterprises. In the process of helping the world fight against the new coronavirus, Chinese vaccine companies can be said to have truly broken the previous monopoly of the international giants on the international vaccine market, and achieved multi-dimensional international development such as exporting products, technologies, brands and services overseas. In the future, Chinese companies going global through platforms such as the 'One Belt, One Road' will change from 'optional' to 'required', from 'additional questions' to 'must-answer questions', and will become a new business growth curve for enterprises.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is China's leading biotech enterprise. With the mission of 'providing vaccines to eliminate diseases for humans', it is committed to the research of human vaccines and related products. Development, production and sales to provide services for global disease prevention and control.
The vaccines developed by SINOVAC mainly include vaccines against viral hepatitis, influenza, pneumonia, polio, chickenpox, mumps and other common infectious diseases, as well as vaccines against SARS, H5N1 avian influenza, H1N1 pandemic influenza, EV71 hand, foot and mouth disease, novel Vaccines for emerging and emerging infectious diseases such as coronavirus infections.
The company's current 4 vaccines have passed World Health Organization pre-certification (inactivated hepatitis A vaccine, Sabin strain inactivated polio vaccine, live attenuated chickenpox vaccine) or are included in the emergency use list (new coronavirus inactivated vaccine). The quality of the vaccines is The management system has been recognized by international organizations and multinational drug regulatory authorities.
SINOVAC is constantly exploring opportunities in the international market and has exported vaccines to dozens of countries and international organizations.
Contact:
Tel: +86-10-8279-9800
Email: sinovac@sinovac.com
SINOVAC BIOTECH LTD. 
